SEC Form 4 · accession 0001209191-19-015927
Protagonist Therapeutics, Inc · PTGX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard S. Shames
Officer — Chief Medical Officer
Period of report
Feb 28, 2019
Accepted (ET)
Mar 4, 2019 · 6:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001377121
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 28, 2019 | A | 8,500 | $0.00 | A | 32,678 | D | |
| Common Stock | Mar 1, 2019 | S | 657 | $8.03 | D | 32,021 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $8.02 | Feb 28, 2019 | A | 51,000 | A | — | Feb 27, 2029 | Common Stock | 51,000 | 51,000 | D |
Explanation of responses
- F1Represents grant of the restricted stock units payable solely in common stock that vest in equal annual installments over four years from the grant date.
- F2The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
- F3The stock option vests in 48 equal monthly installments following the date of grant.